Skip to main content
72°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eaton Vance Ohio Municipal Income Trust
(NQ:
EVO
)
3.770
+0.060 (+1.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eaton Vance Ohio Municipal Income Trust
< Previous
1
2
3
4
Next >
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
January 26, 2023
Via
ACCESSWIRE
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
December 16, 2022
Via
ACCESSWIRE
Evotec SE Reports Results for the First Nine Months 2022 and Provides Corporate Update
November 09, 2022
Via
ACCESSWIRE
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
November 03, 2022
Via
ACCESSWIRE
Evotec Completes Acquisition of Central Glass Germany
November 03, 2022
Via
ACCESSWIRE
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
October 17, 2022
Via
ACCESSWIRE
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
November 02, 2022
Via
ACCESSWIRE
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
October 28, 2022
Via
ACCESSWIRE
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
October 25, 2022
Via
ACCESSWIRE
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
October 18, 2022
Via
ACCESSWIRE
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
October 17, 2022
From
Toronto Innovation Acceleration Partners
Via
Business Wire
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
September 20, 2022
Via
ACCESSWIRE
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
September 16, 2022
Via
ACCESSWIRE
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
August 25, 2022
Via
ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
August 11, 2022
Via
ACCESSWIRE
Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
August 10, 2022
Via
ACCESSWIRE
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
August 10, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
August 04, 2022
Via
ACCESSWIRE
Evotec SE Reports Results of Annual General Meeting 2022
June 22, 2022
HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the...
From
Evotec SE
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Evotec Enters a Drug Discovery Collaboration with Janssen
June 14, 2022
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...
From
Evotec SE
Via
AccessWire
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
May 30, 2022
CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING
From
Evotec AE
Via
AccessWire
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
May 19, 2022
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global...
From
Evotec AG
Via
AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
May 10, 2022
HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and...
From
Evotec AG
Via
AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
May 10, 2022
- 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS - COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING...
From
Evotec AG
Via
AccessWire
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Evotec AG
Via
AccessWire
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
April 12, 2022
- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY...
From
Evotec AG
Via
AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
April 08, 2022
- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A...
From
Evotec AG
Via
AccessWire
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
April 05, 2022
HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April...
From
Evotec AG
Via
AccessWire
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
March 21, 2022
- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR...
From
Evotec AG
Via
AccessWire
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
March 02, 2022
- LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE - ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND...
From
Evotec AG
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.